1. Home
  2. Press release
Oct 01, 2019 11:46 JST

Source: Eisai

Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

TOKYO, Oct 01, 2019 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, announced final results from the full endometrial cancer cohort of KEYNOTE- 146/Study 111 evaluating LENVIMA, an orally available kinase inhibitor discovered by Eisai , plus KEYTRUDA, Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy. The findings were presented in a proffered paper presentation at the European Society for Medical Oncology (ESMO) 2019 Congress (Abstract #994O).

For the full report, visit https://www.eisai.com/news/2019/pdf/enews201977pdf.pdf.

Contact:
Eisai Co., Ltd. 
Media Relations 
+81-(0)3-3817-5120

Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations 
Pamela Eisele: (267) 305-3558 
Kristen Drake: (908) 334-4688
Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
January 26 2026 10:37 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
January 21 2026 15:44 JST
 
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
 
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
 
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
 
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
December 04 2025 17:36 JST
 
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 03 2025 17:19 JST
 
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
December 02 2025 23:01 JST
 
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
November 28 2025 22:00 JST
 
More Press release >>

Latest Press Release


Fujitsu's Takane LLM successfully piloted in central government agency to streamline public comment operations
Feb 03, 2026 11:14 JST

EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions
Feb 03, 2026 10:00 JST

SGL Golf Launches in U.S. Market to Meet Demand for Autonomous Course Management Solutions
Feb 03, 2026 03:00 JST

Lockheed Martin and Fujitsu to accelerate dual-use technology development
Feb 02, 2026 16:29 JST

Fujitsu introduces biometric authentication service for SMBC Nikko Securities Online Trading
Feb 02, 2026 14:30 JST

JCB Launches Usage Promotion Campaign for Inbound Visitors in Fukuoka's Tenjin Area
Feb 02, 2026 10:00 JST

NTT DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion
Jan 30, 2026 22:50 JST

ANIME TOKYO STATION ON ROBLOX: Commemorating the One-Year Anniversary with Gifts and a Wealth of Add-on Content
Jan 30, 2026 09:00 JST

MAZDA CX-5 Achieves Five Million Units in Global Production and Sales
Jan 29, 2026 16:15 JST

The Executive Centre Celebrates 25 Years in Japan: A Commitment to Long-Term Growth and Investment
Jan 29, 2026 12:00 JST

Hitachi reinvents Ellipse Enterprise Asset Management (EAM) solution with Microsoft's AI-enabled technology to improve critical infrastructure resilience
Jan 29, 2026 10:14 JST

TANAKA Recognized as a "Tokyo Sports Promotion Company" for the 11th Consecutive Year
Jan 28, 2026 22:00 JST

NTT, DOCOMO, and NTT DATA to Exhibit at MWC Barcelona 2026
Jan 28, 2026 18:29 JST

MHI Thermal Systems Receives "Minister of Economy, Trade and Industry Award" and MHI's Aerospace Parts Factory Receives "Agency for Natural Resources and Energy Commissioner's Award" at 2025 Energy Conservation Grand Prize Awards
Jan 28, 2026 18:08 JST

Mitsubishi Power Completes GTCC Upgraded Reliability Package at VPI's Damhead Creek Power Station
Jan 28, 2026 17:58 JST

Fujitsu and Tokai National Higher Education and Research System develop space weather prediction capabilities technology leveraging AI
Jan 28, 2026 10:55 JST

NEC Develops High-Efficiency, Compact Power Amplifier Module for 5G Base Station Radio Units
Jan 28, 2026 10:05 JST

Shoucheng Holdings-Backed Robotics Firms Set to Appear at 2026 CMG New Year's Gala
Jan 28, 2026 09:35 JST

The 19th Asian Financial Forum concludes successfully
Jan 27, 2026 23:27 JST

NTT DOCOMO Develops a Solution to Streamline DOOH Advertiser Review Operations
Jan 27, 2026 10:25 JST
 More Latest Release >>